|Other Names||RalBP1-associated Eps domain-containing protein 2, Partner of RalBP1, RalBP1-interacting protein 2, REPS2, POB1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13131a was selected from the N-term region of REPS2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Involved in growth factor signaling through its influence on the Ral signaling pathway.|
|Tissue Location||Expressed at high levels in the cerebrum, cerebellum, lung, kidney, and testis. Weakly expressed in the kidney. Relatively highly expressed in androgen-dependent as compared to androgen-independent prostate cancer cell lines and xenografts. Isoform 2 is down-regulated during progression of prostate cancer|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The product of this gene is part of a protein complex thatregulates the endocytosis of growth factor receptors. The encodedprotein directly interacts with a GTPase activating protein thatfunctions downstream of the small G protein Ral. Its expression cannegatively affect receptor internalization and inhibit growthfactor signaling. Multiple transcript variants encoding differentisoforms have been found for this gene.
Doolan, P., et al. Tumour Biol. 30(4):200-209(2009)Singhal, S.S., et al. J. Biol. Chem. 283(28):19714-19729(2008)Yadav, S., et al. Biochem. Biophys. Res. Commun. 328(4):1003-1009(2005)Oosterhoff, J.K., et al. Int. J. Cancer 113(4):561-567(2005)Penninkhof, F., et al. Oncogene 23(33):5607-5615(2004)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.